Treatments such as JAK inhibitors, biologics, PDE4 inhibitors, and microbial therapy not only fill gaps in traditional therapies but also have the potential to induce complete or nearly complete regression of skin lesions, significantly enhancing patients' quality of life and offering renewed hope for those with refractory AD. Here, PDE4A is linked to Alzheimer disease.